<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Do I Need to Take Ozempic Forever? An Honest Answer – Élan Clinic</title>
  <meta name="description" content="STEP 4 showed 14% weight regain within a year of stopping semaglutide. But chronic disease framing changes everything. A physician gives an honest answer to the question everyone asks." />
  <link rel="canonical" href="https://elan.clinic/blog/do-i-need-ozempic-forever.html" />
  <link rel="icon" type="image/svg+xml" href="/favicon.svg" />

  <!-- Open Graph -->
  <meta property="og:type" content="article" />
  <meta property="og:url" content="https://elan.clinic/blog/do-i-need-ozempic-forever.html" />
  <meta property="og:title" content="Do I Need to Take Ozempic Forever? An Honest Answer" />
  <meta property="og:description" content="STEP 4 showed 14% weight regain within a year of stopping semaglutide. But chronic disease framing changes everything. A physician gives an honest answer." />
  <meta property="og:locale" content="en_GB" />
  <meta property="article:published_time" content="2026-03-01" />
  <meta property="article:author" content="Dr. Ingmar Lindström" />

  <!-- Schema.org MedicalWebPage -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "MedicalWebPage",
    "name": "Do I Need to Take Ozempic Forever? An Honest Answer",
    "headline": "Do I Need to Take Ozempic Forever? An Honest Answer",
    "url": "https://elan.clinic/blog/do-i-need-ozempic-forever.html",
    "datePublished": "2026-03-01",
    "inLanguage": "en",
    "description": "STEP 4 showed 14% weight regain within a year of stopping semaglutide. But chronic disease framing changes everything. A physician gives an honest answer to the question everyone asks.",
    "about": {
      "@type": "MedicalCondition",
      "name": "Obesity"
    },
    "medicalAudience": {
      "@type": "MedicalAudience",
      "audienceType": "Patient"
    },
    "author": {
      "@type": "Person",
      "name": "Dr. Ingmar Lindström",
      "jobTitle": "Physician",
      "worksFor": {
        "@type": "MedicalClinic",
        "name": "Élan Clinic",
        "url": "https://elan.clinic"
      }
    },
    "publisher": {
      "@type": "MedicalClinic",
      "name": "Élan Clinic",
      "url": "https://elan.clinic",
      "logo": "https://elan.clinic/favicon.svg",
      "telephone": "+37252999399",
      "address": {
        "@type": "PostalAddress",
        "streetAddress": "Sepapaja 12/1",
        "addressLocality": "Tallinn",
        "postalCode": "11415",
        "addressCountry": "EE"
      }
    },
    "mainEntityOfPage": {
      "@type": "WebPage",
      "@id": "https://elan.clinic/blog/do-i-need-ozempic-forever.html"
    },
    "citation": [
      {
        "@type": "ScholarlyArticle",
        "name": "STEP 4: Sustained weight management with semaglutide — withdrawal and regain",
        "isPartOf": { "@type": "Periodical", "name": "JAMA" },
        "datePublished": "2021"
      },
      {
        "@type": "ScholarlyArticle",
        "name": "SURMOUNT-4: Continued tirzepatide versus withdrawal after weight loss",
        "isPartOf": { "@type": "Periodical", "name": "JAMA" },
        "datePublished": "2024"
      }
    ]
  }
  </script>

  <!-- Google Fonts -->
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=Playfair+Display:ital,wght@0,400;0,500;0,600;0,700;1,400;1,500&family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet" />

  <style>
    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; font-size: 16px; }
    body {
      font-family: 'Inter', sans-serif;
      background-color: #0D1B2A;
      color: rgba(232, 228, 222, 0.55);
      line-height: 1.7;
      -webkit-font-smoothing: antialiased;
    }
    h1, h2, h3, h4 { font-family: 'Playfair Display', serif; color: #E8E4DE; line-height: 1.2; font-weight: 500; }
    a { color: #C5A55A; text-decoration: none; }
    a:hover { text-decoration: underline; }
    .container { width: 100%; max-width: 1200px; margin: 0 auto; padding: 0 24px; }
    .label { display: inline-block; font-family: 'Inter', sans-serif; font-size: 0.7rem; font-weight: 600; letter-spacing: 0.18em; text-transform: uppercase; color: #C5A55A; margin-bottom: 20px; }
    .gold-line { width: 48px; height: 2px; background: #C5A55A; margin: 28px 0; }
    .nav { position: fixed; top: 0; left: 0; right: 0; z-index: 100; padding: 20px 24px; display: flex; align-items: center; justify-content: space-between; background: rgba(13, 27, 42, 0.92); backdrop-filter: blur(12px); border-bottom: 1px solid rgba(197, 165, 90, 0.12); }
    .nav__logo { font-family: 'Playfair Display', serif; font-size: 1.25rem; color: #E8E4DE; letter-spacing: 0.06em; text-decoration: none; }
    .nav__logo span { color: #C5A55A; }
    .nav__links { display: flex; align-items: center; gap: 32px; list-style: none; }
    .nav__links a { font-size: 0.78rem; font-weight: 500; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.65); text-decoration: none; transition: color 0.2s; }
    .nav__links a:hover, .nav__links a.active { color: #C5A55A; }
    .breadcrumb { padding: 120px 0 0; background-color: #0D1B2A; }
    .breadcrumb__inner { display: flex; align-items: center; gap: 8px; flex-wrap: wrap; }
    .breadcrumb__item { font-size: 0.75rem; font-weight: 500; letter-spacing: 0.08em; color: rgba(232, 228, 222, 0.4); text-transform: uppercase; }
    .breadcrumb__item a { color: rgba(232, 228, 222, 0.4); text-decoration: none; transition: color 0.2s; }
    .breadcrumb__item a:hover { color: #C5A55A; text-decoration: none; }
    .breadcrumb__sep { font-size: 0.7rem; color: rgba(197, 165, 90, 0.4); }
    .breadcrumb__item--current { color: #C5A55A; }
    .article-header { padding: 48px 0 64px; background-color: #0D1B2A; position: relative; overflow: hidden; }
    .article-header::before { content: ''; position: absolute; top: -100px; right: -150px; width: 500px; height: 500px; background: radial-gradient(circle, rgba(197,165,90,0.05) 0%, transparent 70%); pointer-events: none; }
    .article-header__content { max-width: 780px; }
    .article-header h1 { font-size: clamp(2rem, 4.5vw, 3.2rem); line-height: 1.15; margin-bottom: 28px; }
    .article-meta { display: flex; align-items: center; flex-wrap: wrap; gap: 24px; padding-top: 24px; border-top: 1px solid rgba(197, 165, 90, 0.15); }
    .article-meta__item { display: flex; align-items: center; gap: 8px; font-size: 0.8rem; color: rgba(232, 228, 222, 0.5); }
    .article-meta__item strong { color: rgba(232, 228, 222, 0.75); font-weight: 500; }
    .article-meta__dot { width: 3px; height: 3px; border-radius: 50%; background: rgba(197, 165, 90, 0.4); }
    .article-body { padding: 0 0 100px; background-color: #0D1B2A; }
    .article-body__inner { max-width: 780px; }
    .article-body p { font-size: 1.05rem; color: rgba(232, 228, 222, 0.72); line-height: 1.85; margin-bottom: 28px; }
    .article-body h2 { font-size: clamp(1.5rem, 2.5vw, 2rem); margin: 56px 0 20px; color: #E8E4DE; }
    .article-body h3 { font-size: clamp(1.1rem, 2vw, 1.35rem); margin: 40px 0 16px; color: #E8E4DE; }
    .article-body strong { color: rgba(232, 228, 222, 0.9); font-weight: 600; }
    .article-body em { color: rgba(232, 228, 222, 0.65); font-style: italic; }
    .article-body hr { border: none; height: 1px; background: rgba(197, 165, 90, 0.15); margin: 48px 0; }
    .pull-quote { border-left: 3px solid #C5A55A; padding: 20px 32px; margin: 40px 0; background: rgba(197, 165, 90, 0.04); }
    .pull-quote p { font-family: 'Playfair Display', serif; font-size: 1.2rem !important; font-style: italic; color: rgba(232, 228, 222, 0.82) !important; line-height: 1.6 !important; margin: 0 !important; }
    .key-stat { background: #111D2E; border: 1px solid rgba(197, 165, 90, 0.18); padding: 32px 36px; margin: 40px 0; }
    .key-stat__number { font-family: 'Playfair Display', serif; font-size: 3rem; color: #C5A55A; line-height: 1; margin-bottom: 8px; }
    .key-stat__label { font-size: 0.88rem; color: rgba(232, 228, 222, 0.6); line-height: 1.5; }
    .article-sources { margin-top: 60px; padding-top: 32px; border-top: 1px solid rgba(197, 165, 90, 0.12); }
    .article-sources p { font-size: 0.82rem !important; color: rgba(232, 228, 222, 0.38) !important; line-height: 1.6 !important; margin-bottom: 8px !important; }
    .article-sources .sources-label { font-size: 0.7rem; font-weight: 600; letter-spacing: 0.15em; text-transform: uppercase; color: #C5A55A; margin-bottom: 16px; display: block; }
    .back-link { display: inline-flex; align-items: center; gap: 8px; font-size: 0.78rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; color: rgba(232, 228, 222, 0.5); text-decoration: none; transition: color 0.2s, gap 0.2s; margin-bottom: 60px; }
    .back-link:hover { color: #C5A55A; gap: 12px; text-decoration: none; }
    .footer-cta { background-color: #111D2E; border-top: 1px solid rgba(197, 165, 90, 0.12); text-align: center; padding: 100px 24px; }
    .footer-cta h2 { max-width: 620px; margin: 0 auto 24px; font-size: clamp(1.6rem, 3vw, 2.2rem); }
    .footer-cta__sub { max-width: 480px; margin: 0 auto 40px; font-size: 0.95rem; }
    .btn { display: inline-block; padding: 16px 36px; font-family: 'Inter', sans-serif; font-size: 0.85rem; font-weight: 600; letter-spacing: 0.1em; text-transform: uppercase; border: 1.5px solid #C5A55A; color: #C5A55A; background: transparent; cursor: pointer; transition: background 0.2s, color 0.2s; text-decoration: none; }
    .btn:hover { background: #C5A55A; color: #0D1B2A; text-decoration: none; }
    .btn--filled { background: #C5A55A; color: #0D1B2A; }
    .btn--filled:hover { background: #d4b56a; color: #0D1B2A; }
    .footer-legal { background-color: #0D1B2A; border-top: 1px solid rgba(197, 165, 90, 0.08); padding: 40px 24px; }
    .footer-legal__inner { max-width: 1200px; margin: 0 auto; display: flex; flex-direction: column; gap: 8px; }
    .footer-legal p { font-size: 0.75rem; color: rgba(232, 228, 222, 0.3); line-height: 1.6; }
    @media (max-width: 768px) {
      .nav__links { gap: 16px; }
      .nav__links a { font-size: 0.72rem; }
      .breadcrumb { padding-top: 100px; }
      .article-header { padding: 32px 0 48px; }
      .article-body p { font-size: 0.98rem; }
      .key-stat__number { font-size: 2.4rem; }
      .pull-quote { padding: 16px 20px; }
    }
  </style>
</head>
<body>

  <!-- ═══ Navigation ══════════════════════════════════════════════════════ -->
  <nav class="nav">
    <a href="/" class="nav__logo">Élan<span>.</span></a>
    <ul class="nav__links">
      <li><a href="/">Home</a></li>
      <li><a href="/blog.html" class="active">Articles</a></li>
      <li><a href="/faq.html">FAQ</a></li>
      <li style="margin-left:8px;border-left:1px solid rgba(197,165,90,0.25);padding-left:16px;display:flex;gap:12px;"><a href="/et.html" style="font-size:0.7rem;">EST</a> <a href="/ukk.html" style="font-size:0.7rem;">FIN</a> <a href="/voprosy.html" style="font-size:0.7rem;">RUS</a></li>
      <li><a href="/#consultation" class="btn" style="padding: 10px 20px; font-size: 0.72rem;">Book a Consultation</a></li>
    </ul>
  </nav>

  <!-- ═══ Breadcrumb ══════════════════════════════════════════════════════ -->
  <div class="breadcrumb">
    <div class="container">
      <nav class="breadcrumb__inner" aria-label="Breadcrumb">
        <span class="breadcrumb__item"><a href="/">Home</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item"><a href="/blog.html">Articles</a></span>
        <span class="breadcrumb__sep">›</span>
        <span class="breadcrumb__item breadcrumb__item--current">Do I Need Ozempic Forever?</span>
      </nav>
    </div>
  </div>

  <!-- ═══ Article Header ══════════════════════════════════════════════════ -->
  <header class="article-header">
    <div class="container">
      <div class="article-header__content">
        <span class="label">GLP-1 Medications · Long-Term Use</span>
        <h1>Do I Need to Take Ozempic Forever? An Honest Answer</h1>
        <div class="article-meta">
          <div class="article-meta__item">
            <strong>Dr. Ingmar Lindström</strong>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            <time datetime="2026-03-01">March 1, 2026</time>
          </div>
          <div class="article-meta__dot"></div>
          <div class="article-meta__item">
            11 min read
          </div>
        </div>
      </div>
    </div>
  </header>

  <!-- ═══ Article Body ═════════════════════════════════════════════════════ -->
  <main class="article-body">
    <div class="container">
      <div class="article-body__inner">

        <div class="pull-quote">
          <p>"You cannot step into the same river twice." — Heraclitus</p>
        </div>

        <p>
          The pre-Socratic philosopher's point was that the river changes constantly — and so do you. It's a useful frame for the question I'm asked more than almost any other in obesity medicine: <em>Do I have to stay on this medication forever?</em>
        </p>

        <p>
          The honest answer is: for most people, probably yes — if the goal is to maintain the weight loss. But that answer contains several important layers, and collapsing it to a simple yes or no does a disservice to the biology involved, the evidence we have, and the conversation about what chronic disease management actually means.
        </p>

        <p>Let me walk through what we know.</p>

        <hr />

        <h2>What the Withdrawal Data Actually Shows</h2>

        <p>
          The STEP 4 trial was designed specifically to answer the question of what happens when people stop semaglutide. After a 20-week run-in period in which all participants lost an average of 10.6% of body weight, 803 people were randomised to either continue semaglutide 2.4 mg or switch to placebo for a further 48 weeks.
        </p>

        <div class="key-stat">
          <div class="key-stat__number">+14%</div>
          <div class="key-stat__label">Average weight regain within 48 weeks of stopping semaglutide in the STEP 4 withdrawal arm (n=803) — while those who continued semaglutide lost a further 7.9% of body weight over the same period.</div>
        </div>

        <p>
          Those who continued semaglutide lost a further 7.9% of body weight over those 48 weeks. Those who switched to placebo regained 6.9% — which, starting from a base of –10.6%, means they gave back roughly two-thirds of what they had lost. Cardiometabolic markers — blood pressure, waist circumference, glycaemic indices — all deteriorated in the placebo group and continued to improve in the semaglutide group.
        </p>

        <p>
          SURMOUNT-4 replicated this pattern for tirzepatide. After a 36-week run-in (mean 20.9% weight loss), 783 people were randomised to continue tirzepatide or switch to placebo. The withdrawal group regained an average of 14% of body weight at 88 weeks. The continuation group lost a further 5.5%.
        </p>

        <p>
          These are sobering numbers. They tell us clearly that GLP-1 and GIP/GLP-1 medications are suppressing something — appetite, metabolic rate, reward signalling around food — that returns when the medication stops. The underlying biology doesn't change because you've been on the drug for a year.
        </p>

        <hr />

        <h2>The Chronic Disease Framework: Why This Is the Wrong Lens</h2>

        <p>
          The reason the "do I need this forever?" question is so charged is that it implies failure — the sense that a medication working properly is somehow inferior to a cure. We don't ask people with hypertension whether they'll need antihypertensives forever. We don't ask people with hypothyroidism whether they'd prefer not to take levothyroxine indefinitely. We accept that chronic conditions require ongoing management.
        </p>

        <p>
          Obesity is a chronic, relapsing neurobiological condition. That's not a political statement — it's the framing endorsed by the European Association for the Study of Obesity, the American Medical Association, the WHO, and the research consensus represented by the Lancet Commission on Obesity (Jensen et al., 2024). The brain's regulation of body weight is altered in obesity in ways that persist long after weight is lost. The physiological drivers of regain — elevated ghrelin, suppressed leptin, reduced resting metabolic rate, altered reward circuitry — do not normalise with weight loss alone.
        </p>

        <p>
          GLP-1 receptor agonists work by modulating the very neurobiological systems — hypothalamic appetite circuits, mesolimbic reward pathways, gastric motility — that are dysregulated in obesity. When you stop the medication, those systems revert. The weight comes back not because you failed, but because the biological correction was removed.
        </p>

        <p>
          Understanding this changes the conversation entirely. We're not talking about willpower or discipline. We're talking about whether a chronic condition requires ongoing pharmacological management. In most cases, the evidence says it does.
        </p>

        <hr />

        <h2>But It's More Nuanced Than That</h2>

        <p>
          Saying "most people will need ongoing medication" is not the same as saying "everyone does" or "nothing else matters." There is meaningful variation in outcomes after stopping GLP-1 therapy, and the factors that predict better maintenance are identifiable.
        </p>

        <h3>People who fare best after stopping tend to share certain characteristics</h3>

        <p>
          They've used the period of pharmaceutical appetite suppression to build — genuinely build — behavioural infrastructure: consistent exercise habits, nutritional patterns that don't depend on constant restriction, and a working relationship with hunger signals that has changed over time. The medication created a window of reduced appetite that they used not just to eat less, but to restructure how they relate to food and physical activity.
        </p>

        <p>
          This doesn't mean willpower triumphed over biology. It means that the neuroplasticity of habit formation — which is real and measurable — has its own inertia, and some people use the treatment period to establish habits robust enough to maintain partial benefit after stopping.
        </p>

        <h3>The Jensen 2024 framework</h3>

        <p>
          The 2024 Lancet review by Jensen and colleagues proposed a stratified approach to long-term GLP-1 therapy: higher-risk individuals (those with significant cardiovascular comorbidities, severe obesity, or a history of marked regain) should be considered for indefinite treatment; lower-risk individuals who have demonstrated stable weight maintenance over 6–12 months at a stable dose may be candidates for a supervised, structured dose reduction and withdrawal, with close monitoring and a predetermined plan to re-initiate if regain exceeds a defined threshold.
        </p>

        <p>
          This is a far more useful clinical framework than "forever or not." It acknowledges that some people will manage better off medication than the STEP 4 data suggests, while protecting those at highest risk of rapid and complete regain.
        </p>

        <hr />

        <h2>The Dose Reduction Question</h2>

        <p>
          A related question I hear frequently is: <em>can I stay on a lower dose indefinitely rather than the full therapeutic dose?</em>
        </p>

        <p>
          The data here is less clear. Semaglutide is dose-dependent in its effects — 1.0 mg produces less weight loss than 2.4 mg. But the SUSTAIN and STEP trials weren't designed as long-term dose comparison studies, and we don't have good evidence on the minimum effective maintenance dose for weight maintenance specifically. Some clinicians use dose reduction as part of a step-down strategy; others maintain the approved therapeutic dose. In my practice, I approach dose reduction cautiously: I look at whether weight is stable at the current dose, discuss the risk of regain explicitly, and only reduce if the person has demonstrated robust behavioural habits and understands the monitoring protocol.
        </p>

        <p>
          What the data does tell us is that abrupt stopping, without a structured transition plan, is the approach most likely to produce rapid, complete regain. If you are considering stopping, the conversation about how to stop should happen before you stop — with time to build reserves, reinforce habits, and establish a clear re-initiation threshold.
        </p>

        <hr />

        <h2>The Cost and Access Reality</h2>

        <p>
          I would be dishonest if I didn't address the practical dimension. Semaglutide 2.4 mg costs several hundred euros per month without state subsidy, and in most European countries — including Estonia — obesity pharmacotherapy is not reimbursed. For many people, the question of long-term therapy is not purely clinical; it is financial.
        </p>

        <p>
          This matters because it shapes how we should use the treatment window. If indefinite therapy is financially out of reach, the clinical priority shifts toward maximising the structural changes — habits, fitness, nutritional patterns — that provide the most durable benefit after stopping. It also strengthens the argument for the most intensive programme possible during the treatment period, rather than relying on the medication to do the work alone.
        </p>

        <p>
          Healthcare systems are slowly reckoning with this. The ICER (Institute for Clinical and Economic Review) analysis of semaglutide for obesity found cost-effectiveness comparable to other cardiovascular medications at current pricing, particularly for high-risk populations. Reimbursement policies are shifting in some countries. But today, for most people reading this, the cost question is real and needs honest acknowledgment.
        </p>

        <hr />

        <h2>What I Actually Tell People in Clinic</h2>

        <p>
          When someone asks me directly — do I need this forever? — I say something like this:
        </p>

        <p>
          "The evidence is clear that most people who stop this medication will regain a significant portion of the weight, usually within a year. That's not a personal failure — it's the biology of obesity, which is a chronic condition requiring ongoing management, the same way hypertension or hypothyroidism do. Whether you stay on it long-term, step down the dose, or eventually stop depends on how your body responds, what habits you've built, your cardiovascular risk profile, and what's financially and practically sustainable for you. My job is to help you make that decision with accurate information — not to tell you the answer is automatically yes or automatically no."
        </p>

        <p>
          That's honest. It's also, I think, the most clinically useful framing — because it places the decision in context rather than making it feel like a verdict.
        </p>

        <hr />

        <h2>The Physician's Summary</h2>

        <p>
          STEP 4 and SURMOUNT-4 are unambiguous: stopping semaglutide or tirzepatide after significant weight loss leads to substantial regain for the majority of people. The biology driving this is not weakness — it is the restoration of dysregulated appetite and metabolic signals that the medication was suppressing.
        </p>

        <p>
          The chronic disease framework is the right one. Treating obesity pharmacologically is not fundamentally different from treating other chronic conditions — the medication manages the condition; it doesn't cure the underlying biology. For high-risk individuals, indefinite therapy is clinically justified. For others, a structured withdrawal with close monitoring and a clear re-initiation plan may be appropriate.
        </p>

        <p>
          What is not appropriate is stopping abruptly without a plan, and framing regain as personal failure. The river changes constantly. So does the treatment landscape — and the best programme is one that adapts to where you are, not where you were when you started.
        </p>

        <!-- ═══ Sources ═══════════════════════════════════════════════════ -->
        <div class="article-sources">
          <span class="sources-label">Sources</span>
          <p>Rubino D, Abrahamsson N, Davies M, et al. "Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity." <em>JAMA</em>, 2021;325(14):1414–1425. (STEP 4 trial, n=803)</p>
          <p>Aronne LJ, Sattar N, Horn DB, et al. "Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity." <em>JAMA</em>, 2024;331(1):38–48. (SURMOUNT-4, n=783)</p>
          <p>Jensen MD, Ryan DH, Apovian CM, et al. "Pharmacotherapy for obesity — a chronic disease requiring chronic treatment." <em>The Lancet</em>, 2024.</p>
          <p>Sumithran P, Prendergast LA, Delbridge E, et al. "Long-term persistence of hormonal adaptations to weight loss." <em>NEJM</em>, 2011;365:1597–1604.</p>
        </div>

        <!-- ═══ Back Link ═════════════════════════════════════════════════ -->
        <a href="/blog.html" class="back-link">← Back to Articles</a>

      </div>
    </div>
  </main>

  <!-- ═══ Footer CTA ══════════════════════════════════════════════════════ -->
  <section class="footer-cta">
    <span class="label">Consultation</span>
    <h2>Thinking About Stopping GLP-1 Therapy?</h2>
    <p class="footer-cta__sub">
      A 45-minute consultation to review your options — structured withdrawal protocol, dose reduction, or long-term maintenance — with honest guidance on what the evidence actually supports for your situation.
    </p>
    <a href="tel:+37252999399" class="btn btn--filled">Call +372 52 99939</a>
  </section>

  <!-- ═══ Footer Legal ════════════════════════════════════════════════════ -->
  <footer class="footer-legal">
    <div class="footer-legal__inner">
      <p>© 2026 Élan Clinic · Elan Clinic OÜ · Reg 17338832 · Medical licence L07470 · Sepapaja 12/1, Tallinn 11415</p>
      <p>This article is for informational purposes only and does not constitute medical advice. Consult your physician before changing any medication or health programme.</p>
    </div>
  </footer>

</body>
</html>
